循环suPAR作为自身免疫性肝病纤维化与免疫激活的无创生物标志物
本研究回顾性纳入117例自身免疫性肝病(AILD)、慢性乙型肝炎(CHB)、代谢功能障碍相关脂肪性肝病(MASLD)患者及44例健康对照,采用化学发光免疫分析法检测血清suPAR。结果显示AILD患者suPAR显著升高,与纤维化指标及IgG相关,ROC分析显示其能良好区分AILD与对照、CHB及MASLD。
要点
- AILD患者血清suPAR中位数5.16 ng/mL,显著高于对照、CHB和MASLD。
- suPAR与APRI、FIB-4及LSM强相关,与IgG弱相关。
- suPAR区分AILD与MASLD的AUC达0.944,与CHB为0.724。
核心结论
- 循环suPAR在AILD中升高,反映纤维化和免疫激活,可作为无创生物标志物辅助鉴别AILD与CHB及MASLD。
研究设计与样本
- 回顾性研究,纳入117例患者(AILD 61例、CHB 33例、MASLD 23例)及44例健康对照,采用化学发光免疫分析法检测血清suPAR。
主要发现
- AILD患者suPAR中位数5.16 ng/mL,显著高于对照(3.58 ng/mL)、CHB(3.92 ng/mL)和MASLD(3.13 ng/mL),均P < 0.001。
- suPAR与APRI(r = 0.66)、FIB-4(r = 0.65)和LSM(r = 0.62)强相关,与IgG(r = 0.31)弱相关。
- ROC分析显示suPAR区分AILD与对照的AUC为0.839,与CHB为0.724,与MASLD为0.944。
- suPAR水平较高的患者纤维化更进展,肝损伤生化证据更明显。
临床怎么用
- suPAR可作为无创指标辅助鉴别AILD与CHB及MASLD,并提供不依赖抗体的补充诊断价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Noninvasive assessment of fibrosis in autoimmune liver diseases (AILDs) remains challenging. Soluble urokinase plasminogen activator receptor (suPAR) is a marker of systemic immune activation, but its role in AILDs is unclear. This study aimed to evaluate the diagnostic performance of circulating suPAR in AILDs and its association with fibrosis severity and immune activation. METHODS: A retrospective study included 117 patients with AILDs (n = 61), chronic hepatitis B (CHB, n = 33), metabolic dysfunction-associated steatotic liver disease (MASLD, n = 23), and 44 healthy controls. Serum suPAR was measured by chemiluminescent immunoassay. Correlations with fibrosis indices (APRI, FIB-4), liver stiffness measurement (LSM), and IgG were assessed. ROC analysis evaluated diagnostic accuracy. RESULTS: Serum suPAR was significantly higher in AILDs than in controls, CHB, and MASLD (median 5.16 vs. 3.58, 3.92, and 3.13 ng/mL; all P < 0.001). suPAR correlated strongly with APRI (r = 0.66), FIB-4 (r = 0.65), and LSM (r = 0.62), and modestly with IgG (r = 0.31). ROC analysis demonstrated robust discrimination between AILDs and controls (AUC = 0.839), CHB (AUC = 0.724), and MASLD (AUC = 0.944). Patients with higher suPAR levels exhibited more advanced fibrosis and greater biochemical evidence of liver injury. CONCLUSIONS: Circulating suPAR is elevated in AILDs, reflecting fibrosis and immune activation. suPAR provides complementary, antibody-independent diagnostic value and may serve as a noninvasive biomarker for differentiating AILDs from CHB and MASLD in clinical practice.
引用
- Zhan F, Chen T, Liang J, et al. Circulating suPAR as a noninvasive biomarker of fibrosis and immune activation in autoimmune liver diseases. Clin Chim Acta. 2026. PMID: 41506359. doi:10.1016/j.cca.2026.120831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。